 1.  Short title This Act may be cited as the  Bolstering Innovative Options to Save Immediately on Medicines Act  or the  BIOSIM Act .
 2.  Temporary increase in Medicare part B payment for certain biosimilar biological products  Section 1847A(b)(8) of the Social Security Act (42 U.S.C. 1395w–3a(b)(8)) is amended—  (1)  by redesignating subparagraphs (A) and (B) as clauses (i) and (ii), respectively, and moving the margin of each such redesignated clause 2 ems to the right;  (2) by striking  product .—The amount and inserting the following: “ product .— (A)  In general  Subject to subparagraph (B), the amount  ; and  (3)  by adding at the end the following new subparagraph:  (B)  Temporary payment increase  (i)  In general In the case of a qualifying biosimilar biological product that is furnished during the applicable 5-year period for such product, the amount specified in this paragraph for such product with respect to such period is the sum determined under subparagraph (A), except that clause (ii) of such subparagraph shall be applied by substituting  8 percent  for  6 percent . (ii)  Applicable 5-year period  For purposes of clause (i), the applicable 5-year period for a biosimilar biological product is—  (I)  in the case of such a product for which payment was made under this paragraph as of December 31, 2021, the 5-year period beginning on January 1, 2022; and  (II)  in the case of such a product for which payment is first made under this paragraph during a calendar quarter during the period beginning January 1, 2022, and ending December 31, 2026, the 5-year period beginning on the first day of such calendar quarter during which such payment is first made.  (iii)  Qualifying biosimilar biological product defined For purposes of this subparagraph, the term  qualifying biosimilar biological product  means a biosimilar biological product described in paragraph (1)(C) with respect to which— (I)  in the case of a product described in clause (ii)(I), the average sales price is not more than the average sales price for the reference biological product; and  (II)  in the case of a product described in clause (ii)(II), the wholesale acquisition cost is not more than the wholesale acquisition cost for the reference biological product  . 
